The role of high-throughput antigen testing during a pandemic ‡Asymptomatic use is subject to regulatory approval outside the U.S. †For symptomatic individuals, specimens are to be collected using nasopharyngeal and nasal swabs. **Refer to country-specific VITROS® Immunodiagnostic Products SARS-CoV-2 Antigen Instructions for Use for sensitivity and specificity performance data and intended use. Availability of assays varies by country. market under Emergency Use Authorization with the U.S.
Simple sample preparation for swabs placed in a viral transport medium†,‡.Results are reported as either reactive (positive) or non-reactive (negative) with no gray zone.Excellent specificity and sensitivity, making it a viable alternative to PCR testing**.Capacity to run up to 130 tests per hour on our VITROS® XT 76 Integrated Systems and VITROS® 3600 Immunodiagnostic System.The test is a laboratory immunoassay for the in-vitro qualitative detection of the SARS-CoV-2 nucleocapsid antigen.* This lab-based antigen test provides health care systems and communities more capacity to diagnose individuals quickly and accurately with an active SARS-CoV-2 infection.
